🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Jiangsu Simcere Pharmaceutical clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China and USA registers with Jiangsu Simcere Pharmaceutical as lead sponsor. Synced 26 Sep 2026
19Current trials
13Recruiting now
10Drugs in these trials
2Trial registers
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Jiangsu Simcere Pharmaceutical is the lead sponsor of 19 current clinical trials in our China and USA registers. 13 are recruiting patients now. The most common phase is Phase 1. The drugs named most often in its trials are SIM0270, Everolimus and Exemestane. The most-studied condition is Advanced Solid Cancer.

ClinicalTrials.gov trials by status

  • Recruiting1368%
  • Not yet open15%
  • Active, closed526%

Trials by phase

  • Phase 11579%
  • Phase 3316%
  • Phase 215%
01

Clinical trials sponsored by Jiangsu Simcere Pharmaceutical

19 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
NCT06375044 · Relapsed or Refractory Multiple Myeloma
Phase 1 Recruiting 2024-05 USA, China
Study of SIM0508 Alone and in Combination in Patients With Advanced Solid Tumors
NCT06686745 · ClinicalTrials.gov ↗ · Advanced Solid Tumors
Drug: Olaparib
Phase 1 Recruiting 2024-12 China
A Phase I Study of SIM0686 in Participants With Locally Advanced/Metastatic Solid Tumors
NCT07050459 · ClinicalTrials.gov ↗ · Locally Advanced Solid Tumors
Phase 1 Recruiting 2025-05 China
A Study to Investigate the Safety and Tolerability of SCR-6920 Capsule in Patients With Advanced Malignant Tumors
NCT05528055 · ClinicalTrials.gov ↗ · Solid Tumor, Non Hodgkin Lymphoma
Phase 1 Recruiting 2022-05 China
SIM0613 in Participants With Advanced Solid Tumors
NCT07618260 · ClinicalTrials.gov ↗ · Advanced Solid Cancer
Phase 1 Recruiting 2026-05 China
First in Human Study of SIM0610 in Solid Tumors
NCT07348211 · ClinicalTrials.gov ↗ · Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer
Phase 1 Recruiting 2026-01 China
A Phase I Study of SIM0609 in Adult Participants With Locally Advanced/Metastatic Solid Tumors
NCT07265921 · ClinicalTrials.gov ↗ · Advanced Solid Cancer
Phase 1 Recruiting 2025-11 China
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIM0237 Alone or in Combination with BCG in NMIBC
NCT06186414 · ClinicalTrials.gov ↗ · Non-Muscle-Invasive Bladder Cancer (NMIBC)
Phase 1 Recruiting 2024-01 China
A Study of SIM0689 in Adult Participants With Locally Advanced or Metastatic Solid Tumors
NCT07660432 · ClinicalTrials.gov ↗ · Neoplasms, Malignant
Phase 1 Recruiting 2026-07 China
A Phase I Study of SIM0388 in Participants With Malignant Ascites.
NCT07007988 · ClinicalTrials.gov ↗ · Malignant Ascites
Phase 1 Recruiting 2025-04 China
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Doses of SIM0811 Injection in Healthy Chinese Adult Participants
NCT07345364 · ClinicalTrials.gov ↗ · Health, Subjective
Phase 1 Recruiting 2026-01 China
An Open-Label Drug Interaction Clinical Study to Evaluate Itraconazole, Rifampin, Midazolam and SIM0270 in Chinese Healthy Adult Participants
NCT07357610 · ClinicalTrials.gov ↗ · Healthy Adult Participants
Phase 1 Recruiting 2026-01 China
A Phase Ib/III Study of Suvemcitug Plus FTD/TPI in Participants With Refractory Metastatic Colorectal Cancer
NCT07361003 · ClinicalTrials.gov ↗ · Refractory Metastatic Colorectal Cancer
Phase 3 Recruiting 2025-11 China
A Phase 2 Study to Evaluate the Efficacy, Safety of SIM0278 in Subjects With Moderate to Severe Atopic Dermatitis
NCT07175233 · ClinicalTrials.gov ↗ · Atopic Dermatitis (AD)
Drug: SIM0278
Phase 2 Not yet open 2025-10 China
A Study of SIM0270 Combined With Everolimus vs. Treatment of Physician's Choice in Patients With ER+/HER2- Advanced Breast Cancer (SIMRISE)
NCT06680921 · Locally Advanced or Metastatic Breast Cancer
Phase 3 Active, closed 2024-11 China
A Phase Ⅲ Clinical Study of Combined Cisplatin Versus Placebo Combined With Intracavitary Cisplatin Injection in the Treatment of Malignant Pleural Effusions
NCT04914598 · ClinicalTrials.gov ↗ · Malignant Pleural Effusion
Phase 3 Active, closed 2021-07 China
Phase I Study to Evaluate SIM0270 Alone or in Combination in ER+, HER2- Locally Advanced or Metastatic Breast Cancer
NCT05293964 · ClinicalTrials.gov ↗ · Breast Cancer
Phase 1 Active, closed 2022-05 China
Mass Balance Clinical Trial of SIM0270
NCT06654791 · ClinicalTrials.gov ↗ · Healthy Participants
Phase 1 Active, closed 2024-10 China
A Phase I Study of SIM0532 in Adult Participants With Advanced Solid Tumors
NCT07749703 · ClinicalTrials.gov ↗ · Histologically or Cytologically Confirmed Advanced Solid Tumors
Phase 1 Active, closed 2026-03 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Jiangsu Simcere Pharmaceutical trials

10 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Jiangsu Simcere Pharmaceutical trials

22 conditions
Advanced Solid Cancer2Relapsed or Refractory Multiple Myeloma1Locally Advanced or Metastatic Breast Cancer1Atopic Dermatitis (AD)1Advanced Solid Tumors1Locally Advanced Solid Tumors1Solid Tumor1Non Hodgkin Lymphoma1Advanced Solid Tumours1Non-Small Cell Lung Cancer1Colorectal Cancer1Head and Neck Squamous Cell Carcinoma1Non-Muscle-Invasive Bladder Cancer (NMIBC)1Neoplasms, Malignant1Malignant Ascites1Malignant Pleural Effusion1Health, Subjective1Breast Cancer1Healthy Adult Participants1Healthy Participants1Histologically or Cytologically Confirmed Advanced Solid Tumors1Refractory Metastatic Colorectal Cancer1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1913
Clinical trials in USA11

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Advanced Solid Cancer

SponsorTrials
Arvinas1

Sponsors with the most current trials registered for this condition.

06

Questions about Jiangsu Simcere Pharmaceutical trials

How many clinical trials does Jiangsu Simcere Pharmaceutical sponsor?

Jiangsu Simcere Pharmaceutical is the lead sponsor of 19 current trials on ClinicalTrials.gov in our China and USA registers, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Jiangsu Simcere Pharmaceutical trials recruiting?

Yes. 13 of its 19 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Jiangsu Simcere Pharmaceutical testing?

Its current trials name 10 drugs and biologicals as interventions. The most frequent are SIM0270 (3), Everolimus (2), Exemestane (1), Fulvestrant (1) and Itraconazole (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.